Work

Impact of Margin-to-Depth of Invasion Ratio on Oncologic Outcomes in Locally Advanced Oral Cancer Treated With Surgery and Chemoradiotherapy

Year: 2026

Type: article

Abstract: OBJECTIVES: This study aimed to evaluate the prognostic value of the margin-to-depth of invasion ratio (MDR) in patients with locally advanced oral squamous cell carcinoma (LAOSCC) who underwent curative surgery followed by adjuvant concurrent chemoradiotherapy (CCRT). METHODS: We analyzed 422 consecutive patients with LAOSCC treated at a single institution between 2007 and 2017. MDR was defined as the ratio of the closest surgical margin (mm) to the tumor depth of invasion (mm). Survival outcomes, including overall survival (OS), cancer-specific survival (CSS), and relapse-free survival (RFS), were assessed. The optimal MDR cutoff was determined by X-tile analysis and validated using repeated k-fold cross-validation. RESULTS: The optimal MDR cutoff for predicting survival was 0.35. Patients with MDR ≥0.35 (high MDR, n=205) demonstrated significantly better 5-year OS (66.1% vs. 47.6%, P<0.001), CSS (77.5% vs. 57.4%, P<0.001), and RFS (71.5% vs. 53.8%, P=0.001) than those with MDR <0.35 (low MDR, n=217). In multivariate analysis, low MDR remained an independent adverse prognostic factor for OS (hazard ratio [HR], 1.612; P=0.005), CSS (HR, 2.028; P=0.001) and RFS (HR, 1.501; P=0.033). Among patients with adequate margins (≥5 mm), MDR retained significant prognostic value (OS, P=0.008; CSS, P=0.001; RFS, P=0.015). Cross-validation confirmed the robustness of the MDR threshold value of 0.35 across all survival endpoints. CONCLUSION: MDR is an independent prognostic marker in LAOSCC treated with surgery and adjuvant CCRT. A cutoff of 0.35 effectively stratifies survival risk, even among patients with adequate surgical margins. Incorporating MDR into postoperative assessment could refine risk stratification and guide individualized follow-up and adjuvant treatment planning.

Source: Clinical and Experimental Otorhinolaryngology

DOI: 10.21053/ceo.2025-00339